Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab‐treated and rituximab‐naïve patients. Issue 12 (17th October 2022)
- Record Type:
- Journal Article
- Title:
- Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab‐treated and rituximab‐naïve patients. Issue 12 (17th October 2022)
- Main Title:
- Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab‐treated and rituximab‐naïve patients
- Authors:
- Mazaherpour, Elham
Kianfar, Nika
Dasdar, Shayan
Sedaghat, Mojtaba
Seyrafi, Hassan
Balighi, Kamran
Saberi, Fatemeh
Nili, Ali
Farimani, Zeinab
Azar, Pedram Molhem
Mahmoodi, Hamidreza
Murrell, Dedee F.
Daneshpazhooh, Maryam - Abstract:
- Abstract: Rituximab (RTX) combined with short‐term glucocorticoids (GC) is an effective therapeutic option for pemphigus. The newly developed Glucocorticoid Toxicity Index (GTI) tool provides the possibility to measure GC toxicities over time. To compare 1‐year GTI between two groups of RTX‐treated and RTX‐naïve patients with pemphigus. The responsiveness of the GTI was also investigated. A prospective cohort of 129 adults with newly diagnosed pemphigus was conducted. GC‐related toxicities were assessed at 3‐month intervals according to Composite and Specific lists of the GTI. Of the patients, 76.7% ( n = 99) received RTX. Throughout the time intervals, RTX‐treated patients had lower GTI compared to RTX‐naïve ones ( p = 0.036). The mean GTI at 1‐year was 34.3 in the RTX‐treated group and 50.8 in the RTX‐naïve group ( p = 0.04). The most commonly observed GC‐related toxicity was neuropsychiatric manifestations for 34% (224 events). The relapse rate of RTX‐treated patients (1%) was significantly lower than RTX‐naïve patients (10%) ( p = 0.037). The GTI showed no correlation with cumulative GC consumption in both groups ( p > 0.05, both). Patients treated with GC alone had remarkably higher GTI than patients treated with GC plus RTX. The GTI is an applicable tool to quantitatively capture GC toxicities at the patient level in pemphigus.
- Is Part Of:
- Dermatologic therapy. Volume 35:Issue 12(2022)
- Journal:
- Dermatologic therapy
- Issue:
- Volume 35:Issue 12(2022)
- Issue Display:
- Volume 35, Issue 12 (2022)
- Year:
- 2022
- Volume:
- 35
- Issue:
- 12
- Issue Sort Value:
- 2022-0035-0012-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2022-10-17
- Subjects:
- autoimmune blistering diseases -- COVID‐19 -- glucocorticoid toxicity index (GTI) -- glucocorticoids -- pemphigus -- rituximab
Skin -- Diseases -- Periodicals
Dermatology -- Periodicals
616.5 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=1396-0296;screen=info;ECOIP ↗
http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%291529-8019 ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=dth ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/dth.15902 ↗
- Languages:
- English
- ISSNs:
- 1396-0296
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3555.143000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24709.xml